statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright issued their Q2 2024 EPS estimates for shares of Vigil Neuroscience in a research note issued on Wednesday, March 27th. HC...

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 EPS estimates for Vigil Neuroscience in a report released on Wednesday, March 27th...

Vigil Neuroscience, Inc. Expected to Earn Q1 2024 Earnings of ($0.58) Per Share (NASDAQ:VIGL)

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush lowered their Q1 2024 EPS estimates for shares of Vigil Neuroscience in a report released on Tuesday, March...

Wedbush Analysts Lower Earnings Estimates for Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating on March 27. Graig Suvannavejh h...

Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts

Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP Enrollment for IGNITE trial completed with 20 patients...

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vigil Neuroscience GAAP EPS of -$0.57 in-line...

Vigil Neuroscience GAAP EPS of -$0.57 in-line

Vigil Neuroscience Inc (VIGL Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler...

Buy Rating Affirmed: Vigil Neuroscience's Advancing TREM2 Programs and Strong Financial Position

Vigil Neuroscience: Q4 Earnings Insights

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vigil Neuroscience appoints Kaufmann as Chief Medical Officer

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Watchers	147
52-Wk Low	$2.50
52-Wk High	$11.11

Volume	55,653.00
52-Wk High	$11.11
52-Wk Low	$2.50

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.55	--	--	N/A
Q1'24	-$0.61	-$0.50	17.45%	BEAT
Q4'23	-$0.56	-$0.57	-2.52%	MISSED
Q3'23	-$0.57	-$0.53	7.42%	BEAT
Q2'23	-$0.54	-$0.52	4.21%	BEAT

VIGL Vigil Neuroscience Inc

About

Feed

News

Earnings

Fundamentals